Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.23 Billion CNY | 39.74% |
| 2022 | 880.82 Million CNY | 78.71% |
| 2021 | 492.87 Million CNY | 76.85% |
| 2020 | 278.69 Million CNY | 13.05% |
| 2019 | 246.51 Million CNY | 42.3% |
| 2018 | 173.24 Million CNY | 132.21% |
| 2017 | 74.6 Million CNY | 168.71% |
| 2016 | 27.76 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.5 Billion CNY | 22.2% |
| 2024 Q2 | 1.51 Billion CNY | 0.88% |
| 2024 Q3 | 1.66 Billion CNY | 9.69% |
| 2023 Q4 | 1.23 Billion CNY | 10.92% |
| 2023 Q2 | 1.03 Billion CNY | 10.73% |
| 2023 FY | 1.23 Billion CNY | 39.74% |
| 2023 Q1 | 930.57 Million CNY | 5.65% |
| 2023 Q3 | 1.1 Billion CNY | 7.69% |
| 2022 Q3 | 756.77 Million CNY | 18.99% |
| 2022 Q4 | 880.82 Million CNY | 16.39% |
| 2022 Q2 | 635.98 Million CNY | 10.44% |
| 2022 Q1 | 575.84 Million CNY | 16.83% |
| 2022 FY | 880.82 Million CNY | 78.71% |
| 2021 FY | 492.87 Million CNY | 76.85% |
| 2021 Q1 | 300.36 Million CNY | 7.78% |
| 2021 Q4 | 492.87 Million CNY | 10.5% |
| 2021 Q3 | 446.06 Million CNY | 9.05% |
| 2021 Q2 | 409.02 Million CNY | 36.18% |
| 2020 Q1 | 186.19 Million CNY | -24.47% |
| 2020 FY | 278.69 Million CNY | 13.05% |
| 2020 Q3 | 215.96 Million CNY | 24.21% |
| 2020 Q2 | 173.87 Million CNY | -6.61% |
| 2020 Q4 | 278.69 Million CNY | 29.04% |
| 2019 Q1 | 140.12 Million CNY | -19.12% |
| 2019 Q2 | 198.26 Million CNY | 41.49% |
| 2019 Q3 | 164.7 Million CNY | -16.93% |
| 2019 Q4 | 246.51 Million CNY | 49.67% |
| 2019 FY | 246.51 Million CNY | 42.3% |
| 2018 FY | 173.24 Million CNY | 132.21% |
| 2018 Q4 | 173.24 Million CNY | 0.0% |
| 2017 FY | 74.6 Million CNY | 168.71% |
| 2016 FY | 27.76 Million CNY | 0.0% |